CHARLESTON, SC – Efferent Labs®, a vanguard in biotechnological innovation, today announced a significant expansion of its intellectual property portfolio, reinforcing its leadership status in
(BUFFALO, NY) Apr. 1, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in vivo cellular data, today announced that the United States Patent and Trademark
(BUFFALO, NY) Feb. 15, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in vivo cellular data, today announced that the United States Patent and Trademark
(CHARLESTON, S.C.) Mar 6, 2021/GlobeNewswire/ – Today, Efferent Labs announces an expanded development collaboration with W. L. Gore & Associates, Inc. (Gore) to explore the
Overview Efferent Labs CMO, Dr. Spencer Rosero, was invited to present the findings and efforts of Efferent Labs work in collaboration with Evotec A.G. at
(CHARLESTON, S.C.) Aug. 18, 2020 /PRNewswire/ Efferent Labs and W. L. Gore & Associates (Gore) today announced a collaboration to explore implantable biosensing for long-term chronic disease
FOR IMMEDIATE RELEASE Efferent Labs™ at 2018 NewYorkBIO (BUFFALO, NY) April 24, 2016 – Efferent Labs will present the CytoComm™ BiosensorPlatform at the NYBio Annual
FOR IMMEDIATE RELEASE Efferent Labs™ at 2018 BIO International Convention (BUFFALO, NY) April 15, 2018 – Efferent Labs CEO Bill Rader will present at the
Our transformative technology platform will dramatically reduce R&D costs.
Efferent Labs® offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.
Sign up for email alerts of Press Releases and Efferent Labs’ breaking news
